To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Dose-response relation of liquid aerosol inhaled insulin in type I diabetic patients.
Department of Internal Medicine, Karl-Franzens University, Graz, Austria.
Department of Internal Medicine, Karl-Franzens University, Graz, Austria.
Department of Internal Medicine, Karl-Franzens University, Graz, Austria.
Department of Internal Medicine, Karl-Franzens University, Graz, Austria.
Show others and affiliations
2001 (English)In: Diabetologia, ISSN 0012-186X, E-ISSN 1432-0428, Vol. 44, no 3, p. 305-308Article in journal (Refereed) Published
Abstract [en]

AIMS/HYPOTHESIS: The AERx insulin Diabetes Management system (AERx iDMS) is a liquid aerosol device that enables insulin to be administered to the peripheral parts of the lung. This study aimed to compare the pharmacokinetic and pharmacodynamic properties of insulin which is inhaled using AERx iDMS with insulin which is subcutaneously administered.

METHODS: In total, 18 C-peptide negative patients with Type I (insulin-dependent) diabetes mellitus participated in this randomised, open-label, 5-period crossover trial. Human regular insulin was administered subcutaneously (0.12 U/kg body weight) or inhaled by means of the AERx iDMS (dosages 0.3, 0.6, 1.2, and 1.8 U/kg body weight). Thereafter plasma glucose was kept constant at 7.2 mmol/l for a 10-h period (glucose clamp technique).

RESULTS: Inhaled insulin provided a dose-response relation that was close to linear for both pharmacokinetic (AUC-Ins(0-10 h); Cmax-Ins) and pharmacodynamic (AUC-GIR(0-10 h); GIRmax) parameters. Time to maximum insulin concentration (Tmax-Ins) and time to maximum glucose infusion rate (TGIRmax) were shorter with inhaled insulin than with subcutaneous administration. The pharmacodynamic system efficiency of inhaled insulin (AUC-GIR(0-6 h) was 12.7% (95% C.I.: 10.2-15.6).

CONCLUSION/INTERPRETATION: The inhalation of soluble human insulin using the AERx iDMS is feasible and provides a clear dose response. Further long-term studies are required to investigate safety aspects, HbA1c values, incidence of hypoglycaemic events and the quality of life.

Place, publisher, year, edition, pages
Springer, 2001. Vol. 44, no 3, p. 305-308
Keywords [en]
Type I diabetes, inhaled insulin, pulmonary insulin, pharmacokinetics, pharmacodynamics, insulin therapy
National Category
Endocrinology and Diabetes
Identifiers
URN: urn:nbn:se:oru:diva-74505DOI: 10.1007/s001250051618ISI: 000167663600005PubMedID: 11317660Scopus ID: 2-s2.0-0035084004OAI: oai:DiVA.org:oru-74505DiVA, id: diva2:1319150
Available from: 2019-05-29 Created: 2019-05-29 Last updated: 2019-06-12Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Jendle, Johan

Search in DiVA

By author/editor
Jendle, Johan
In the same journal
Diabetologia
Endocrinology and Diabetes

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 278 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf